An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma A preinfusion circulatory inflammation biomarker-based signature predicts the likelihood of treatment failure in patients with non-Hodgkin lymphoma who were treated with CAR-T cell therapy, with an inflammatory...
The term biomarker refers to a measurement variable that is associated with disease outcome. It can be a single measurement, such as prostate-specific antigen (PSA) level, or a classifier (signature) computed from measures of numerous other variables, such as OncoType DX recurrence score, 1 ...
et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 70, 3870–3876 (2010). Article CAS PubMed Google Scholar Han, B. et al. FOXC1: an emerging marker and therapeutic target for cancer. Oncogene 36, 3957–3963 (2017). ...
In MM, genetic abnormalities detected by interphase FISH have been used extensively for diagnostic and prognostic biomarker purposes [45]. These abnormalities include copy number variations (CNVs) such as hyperdiploidy (trisomies or tetrasomies of odd numbered chromosomes) and focal or chromosome arm ...
This principle was recently demonstrated for both the Mammaprint and Oncotype DX biomarker assays by the MINDACT and TAILOR trials [10, 11]. Biomarker research has increasingly incorporated epigenetic processes, particularly DNA methylation. DNA methylation is the addition of a methyl group to the ...
sST2 is routinely used as prognostic biomarker in patients with HF [13]. However, high circulating levels of sST2 have also been found in subjects with ARDS, asthma and sepsis. [14]. With these considerations in mind, it was supposed that sST2 could be taken as common ground among SARS...
BMC Cancer (2024) 24:89 https://doi.org/10.1186/s12885-023-11796-0 BMC Cancer RESEARCH Open Access EMP3 as a prognostic biomarker correlates with EMT in GBM Li Li1†, Siyu Xia2†, Zitong Zhao3, Lili Deng1, Hanbing Wang4, Dongbo Yang4, Yizhou Hu5, ...
Conclusion Our results indicate that LDHA up-regulation can be a predictor of poor prognosis in clear cell renal cell carcinoma. Thus, it represents a potential prognostic biomarker that can boost the accuracy of other prognostic models in patients with clear cell renal cell carcinoma.Similar...
Microarray data are also the main resources of biomarker candidates [17]. In this study, we integrated data from three mRNA microarray datasets and a microRNA dataset with pathway, functional, and overall survival analysis to identify putative novel pancreatic cancer biomarkers among differentially ...
RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data...